In a significant advancement for internal operations, the U.S. Food and Drug Administration (FDA) has unveiled Elsa 4.0, a revamped version of its artificial intelligence platform. In addition, the agency has integrated over 40 of its data systems into a new platform known as HALO, which is part of a comprehensive modernization effort.
The FDA aims to enhance operational efficiency through these developments, enabling staff—such as scientific reviewers and investigators—to access and analyze data with greater ease. The integration of Elsa with HALO, which stands for Harmonized AI & Lifecycle Operations for Data, will streamline workflows by allowing employees to query agency data without the need for manual document uploads into chat systems.
Marty Makary emphasized that these upgrades are focused on alleviating administrative burdens, leading to improved productivity for agency scientists and reviewers.
“By minimizing tedious tasks for our staff, we enable them to concentrate on scientific endeavors, thereby making their workflow both more efficient and enjoyable,” Makary stated. “Our scientists are among the best globally, and it is crucial that we support them adequately.”
According to the FDA, Elsa 4.0 comes with an array of new features, including customized AI agents, automated document generation, quantitative data analysis, tools for creating charts and graphs, voice-to-text dictation, optical character recognition for scanned documents, and improved search functionalities for expansive document libraries. Furthermore, the platform incorporates secure web search capabilities.
Jeremy Walsh highlighted that integrating Elsa and HALO allows the AI system to function directly atop the agency’s data systems, eliminating the need for staff to upload information manually.
“In the past, FDA staff would need to bring data into Elsa. Now, Elsa operates directly on our data systems,” Walsh explained. “Integrating AI into our workflows is a top priority, enabling us to expedite advancements in regulatory science and deliver more effective treatments to patients more swiftly.”
The FDA has indicated that Elsa operates within a FedRAMP High secure Google Cloud environment, ensuring that it does not train on agency input data or submissions from regulated companies. Importantly, it is not directly connected to the internet, and FDA staff will continue to review and validate any AI-generated outputs.
Since its introduction in June 2025 as Elsa 1.0, the FDA’s Office of Digital Transformation has broadened the functionality of the tool and introduced additional applications aimed at improving regulatory workflows.
Support local news that benefits Chester County. MyChesCo provides reliable, fact-based reporting and crucial community resources—accessible to all. If you value this service, click here to become a patron today.
